Genome&Company

(주)지놈앤컴퍼니 · KOSDAQ · 314130 · Industry: Manufacture of medicinal chemicals

Key metrics

Earnings

Revenue, Q3 2026₩7.2bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ+15.8% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY+10.4% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026-₩7.5bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ+6.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+7.9% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩27.0bn As of Mar 6, 2026 Source 1 ↗
Rights offering new shares, last 12 months1,507,405 shares As of Apr 3, 2026 Source 1 ↗, Source 2 ↗
Potential new shares, last 12 months6,660,076 shares (1 upward conversion price adjustment not netted) As of Oct 13, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4
Potential new shares, % of shares12.7% (1 upward conversion price adjustment not netted) As of Oct 13, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4, Source 5 ↗
Conversion price adjustments, last 12 months2 As of Oct 13, 2026 Source 1 ↗, Source 2

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months4 As of Nov 19, 2026
DART filings, previous 3 months13 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market buys, last 12 months (amount)₩0 As of Nov 19, 2026
Open-market sells, last 12 months (shares)16,000 shares As of Mar 27, 2026 Source 1 ↗, Source 2 ↗
Open-market sells, last 12 months (amount)₩155m As of Mar 27, 2026 Source 1 ↗, Source 2 ↗
Net open-market buying, last 12 months (shares)-16,000 shares As of Mar 27, 2026 Source 1 ↗, Source 2 ↗
Insiders who bought, last 12 months0 As of Nov 19, 2026

Insider transactions (last 12 months)

Open-market buys: 0 shares (₩0). Open-market sells: 16,000 shares (₩155m). Net open-market buying: -16,000 shares. Insiders who bought: 0.

Trade dateInsider (role)TypeSharesPriceAmount
May 21, 2026Park Han-su (Registered director, Controlling shareholder)Other (Gift given)-20,000 shares——
May 21, 2026Cha Mi-yeong (Non-registered officer)Other (Gift received)+20,000 shares——
Apr 23, 2026Seo Jin-gyeong (Non-registered officer)Other (Appraisal right exercise)+26,000 shares₩3,040₩79m
Mar 27, 2026Yoo Hyeon-gyeong (Non-registered officer)Open-market sell-6,000 shares₩10,000₩60m
Mar 26, 2026Seo Jin-gyeong (Non-registered officer)Open-market sell-10,000 shares₩9,455₩95m

Annual financials

YearRevenueOperating income
2025₩24.6bn-₩29.2bn
2024₩27.7bn-₩24.2bn
2023₩14.3bn-₩55.1bn

Filing timeline